Promis Neuroscie Stock Price, News & Analysis

ProMIS Neurosciences Inc. (TSX: PMN; Nasdaq: PMN) announced the submission of an Investigational New Drug (IND) application to the FDA for PMN310, targeting Alzheimer’s disease (AD). This is a significant milestone in advancing PMN310 towards clinical trials, offering potential new treatment options for AD patients. PMN310 selectively targets toxic oligomers of amyloid-beta, a key factor in AD pathology, showing strong binding to these harmful proteins in preclinical studies. The company anticipates transitioning to a clinical-stage entity pending regulatory approval. Management emphasizes the antibody's potential for a differentiated safety profile compared to existing treatments, which often bind to non-targeted plaques, potentially minimizing associated risks.

ProMIS Neurosciences (TSX: PMN) has announced promising results for its lead candidate, PMN310, which targets toxic oligomers linked to Alzheimer’s disease (AD). In a recent presentation at the AD/PD 2023 conference, new preclinical data showed PMN310 selectively binds to these harmful oligomers, differentiating it from other amyloid-beta-directed antibodies. This selectivity may reduce the risk of side effects commonly associated with plaque-binding therapies. ProMIS plans to submit an IND application in the coming weeks for clinical development of PMN310, aiming to advance its treatment options for patients suffering from AD.

ProMIS Neurosciences Inc. (TSX: PMN, Nasdaq: PMN), a biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, announced presentations at the upcoming American Academy of Neurology Annual Meeting, scheduled for April 22-27, 2023, in Boston, MA. The event will feature an oral presentation and two poster presentations on their drug development pipeline, including lead candidate PMN310 for Alzheimer's disease, a new Alzheimer's vaccine, and potential therapeutic target RACK1 for ALS. Dr. Johanne Kaplan will present on the rational design of vaccines and antibody protection against amyloid-beta oligomers.

ProMIS Neurosciences (TSX: PMN, Nasdaq: PMN) announced new preclinical data for its lead Alzheimer's candidate, PMN310, to be presented at the AD/PD 2023 conference from March 28 to April 1, 2023. The presentation, titled 'Differentiation of PMN310 from Other Amyloid-Beta-Directed Antibodies,' will highlight PMN310's selective targeting of toxic brain oligomers. The virtual poster will be accessible during the conference and on ProMIS’ website, emphasizing the company's commitment to developing antibody therapeutics for neurodegenerative diseases. This data could have significant implications for Alzheimer's treatment.

ProMIS Neurosciences (TSX: PMN, Nasdaq: PMN) announced key developments related to its Alzheimer's disease candidate, PMN310, including the completion of preclinical studies and preparations for an IND submission to the FDA within 60 days. The company reported a significant increase in R&D expenses, totaling $16.1 million for 2022, up from $4.6 million in 2021. General and Administrative expenses rose to $7.3 million, compared to $3.7 million in the previous year. The net loss for 2022 was $18.1 million, reflecting the company's investment in advancing its drug development pipeline.

ProMIS Neurosciences Inc. (TSX: PMN, Nasdaq: PMN), a biotechnology firm focused on antibody therapeutics for neurodegenerative diseases, has announced that CEO Gail Farfel, Ph.D., will present at the Oppenheimer 33rd Annual Conference on March 13, 2023, at 12:30 p.m. ET. The presentation will be webcasted and available on ProMIS’ website for 30 days following the event.

The company specializes in targeting toxic misfolded proteins linked to conditions such as Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple system atrophy. ProMIS employs proprietary platforms to discover novel antibody therapeutics.

ProMIS Neurosciences (TSX: PMN) announced a $7.4 million private placement and appointed Gail Farfel, Ph.D. as its CEO as of September 19, 2022. The company is progressing toward an investigational new drug (IND) submission for PMN310, targeting Alzheimer’s disease, with plans to enroll the first subject in a Phase 1a trial in the first half of 2023. Financial highlights for Q3 2022 include a net loss of $6.0 million and research expenses of $4.6 million, up from $0.8 million year-over-year. Cash reserves decreased to $4.0 million.

ProMIS Neurosciences Inc. (Nasdaq: PMN) has closed a fully subscribed private placement of 1,383,755 Units at US$5.40 each, raising gross proceeds of US$7,472,277. Each Unit consists of a Common Share and a quarter Warrant, with each full Warrant exercisable at US$7.50 for five years. Proceeds will fund the first-in-human study of lead candidate PMN310 in 2023, pending FDA approval, while also supporting IP expansion and working capital. ProMIS focuses on developing antibody therapeutics for neurodegenerative diseases like Alzheimer’s, ALS, and MSA.

ProMIS Neurosciences (Nasdaq: PMN) has appointed Gail M. Farfel, Ph.D., as its new Chief Executive Officer, effective September 19, 2022. With over 25 years of experience in neurology drug development, Dr. Farfel aims to lead ProMIS towards becoming a clinical-stage biotechnology company with multiple product opportunities. The company achieved significant milestones in the past 18 months, including a successful Nasdaq listing and the IND submission for their lead Alzheimer’s drug, PMN310, expected by year-end.